ACKR3 and prostate carcinoma: Provided that CXCR7 confers survival and growth advantages to prostate cancer cells, it is surprising that androgen deprivation resistant cell lines (C4-2B and 22Rv1) exhibit lower CXCR7 expression than androgen-dependent lines (LNCaP) as shown in Fig. 1a.